充血性心力衰竭 - The Left Main and Coronary Artery Bifurcation Lesion Summit (CBS)

Abstract

Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction: The DEFINE-HF Trial
Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction
Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status - Results from the EMPEROR-Reduced Trial
Cardiovascular Aging and Heart Failure: JACC Review Topic of the Week
Vaccination Trends in Patients With Heart Failure - Insights From Get With The Guidelines–Heart Failure
Left Ventricular Assist Devices: Synergistic Model Between Technology and Medicine
Antithrombotics From Aspirin to DOACs in Coronary Artery Disease and Atrial Fibrillation (Part 3/5)
Ejection Fraction Pros and Cons: JACC State-of-the-Art Review
Heart Failure With Preserved Ejection Fraction in the Young
Economic and Quality-of-Life Outcomes of Natriuretic Peptide–Guided Therapy for Heart Failure

Original Research

16 Sep 2019

JOURNAL：Circulation.

Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction: The DEFINE-HF Trial

Nassif ME, Windsor S, DEFINE-HF Investigators.

7966

Keywords: SGLT-2 inhibitors; HFrEF; T2DM; Dapagliflozin effect

FULL TEXT PDF